Dossier assessment
Iptacopan (paroxysmal nocturnal haemoglobinuria with haemolytic anaemia) – Assessment according to §35a SGB V (1), Sentence 11
Report documents
-
Dossier assessment
Iptacopan (paroxysmal nocturnal haemoglobinuria with haemolytic anaemia) – Assessment according to §35a SGB V (1), Sentence 11
Project details
- Project no.
- G24-16
- Commission
- Commission awarded on 27.06.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Haematology
- Note
-
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA Website.
- DOI
https://doi.org/10.60584/G24-16
Connected Projects
-
Dossier assessment
Iptacopan (complement 3 glomerulopathy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Iptacopan (complement 3 glomerulopathy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Iptacopan (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed